

AMENDMENT

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of claims:

Claim 1 (currently amended): A conformationally restricted polyamine analog of the formula:

E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH-E

wherein each A is independently selected from the group consisting of: a single bond, C₁-C₆ alkyl, and C₂-C₆ alkenyl;


each B is independently selected from the group consisting of: a single bond, C₁-C₆ alkyl [[,] and C₂-C₆ alkenyl;

and each E is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloaryl, and C₃-C₆ cycloalkenyl;


with the proviso that at least one A moiety is selected from the group consisting of C₂-C₆ alkenyl;

and any salt or stereoisomer thereof.


Claim 2 (original): A conformationally restricted polyamine analog according to claim 1, selected from the group consisting of




,







,




,



,



, and



, and any salt or

stereoisomer thereof.

Claim 3 (currently amended): A conformationally restricted polyamine analog of the formula:

E-NH-B-A-B-NH-B-A-B-NH-B-A-B-NH(-B-A-B-NH)_x-E

wherein each A is independently selected from the group consisting of: a single bond, C₁-C₆ alkyl, and C₂-C₆ alkenyl;


each B is independently selected from the group consisting of: a single bond, C₁-C₆ alkyl [[,] and C₂-C₆ alkenyl;

each E is independently selected from the group consisting of H, C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloaryl, and C₃-C₆ cycloalkenyl; and x is an integer from 2 to 16;


with the proviso that at least one A moiety is selected from the group consisting of C₂-C₆ alkenyl;

and any salt or stereoisomer thereof.

Claim 4 (original): A conformationally restricted polyamine analog according to claim 3, selected from the group consisting of:



and




;


and any salt or stereoisomer thereof.

Claim 5 (currently amended): A polyamine analog of the formula:
E-NH-B-A-B-NH-B-A-B-NH(-B-A-B-NH)_x-E
wherein each A is independently selected from the group consisting of: a single bond and C₂-C₆ alkenyl;
each B is independently selected from the group consisting of: a single bond, C₁-C₆ alkyl [[,]] and C₂-C₆ alkenyl;
each E is independently selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkanol, C₃-C₆ cycloalkanol, and C₃-C₆ hydroxyaryl,
with the proviso that at least one E moiety be selected from the group consisting of C₁-C₆ alkanol, C₃-C₆ cycloalkanol, and C₃-C₆ hydroxyaryl;
and x is an integer from 0 to 16;
and any salt or stereoisomer thereof.


Claim 6 (original): A polyamine analog according to claim 5, selected from the group consisting of:



,



, and



;

and all salts and stereoisomers thereof.

Claims 7-15 (canceled)

Claim 16 (original): ~~The polyamine analog A compound of claim 1, further comprising a pharmaceutically acceptable excipient.~~

Claim 17 (currently amended): A method of treating ~~an indication cancer~~ in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog compound of claim 4 3.

Claim 18 (original): The method of claim 17, wherein the individual is a human.

Claim 19 (canceled)

Claim 20 (currently amended): The method of claim ~~19~~ 17, wherein the cancer affects cells of the bladder, blood, brain, breast, colon, digestive tract, lung, ovaries, pancreas, prostate gland, or skin.

Claim 21 (currently amended) ~~The method of claim 17, wherein the indication is A method of treating a disease in an individual, wherein the disease is selected from Alzheimer's~~

disease, epilepsy, multiple sclerosis, problems associated with tissue grafts and organ transplants, psoriasis, restenosis, stomach ulcers, or tissue overgrowth after surgery, or an infection or infestation of parasites [,] bacteria, or fungi or insects, comprising administering to the individual a therapeutically effective amount of a compound of claim 3.

Claim 22 (currently amended): A method of suppressing cell growth in an individual comprising the step of administering to the individual a therapeutic amount of a polyamine analog compound of claim 1 3.

Claim 23. (original): The method of claim 22, wherein the individual is a human.

Claims 24-31 (canceled)

Claim 32. (currently amended): The method of claim 17, wherein the indication cancer is breast cancer.

Claim 33 (new): A method of treating cancer in an individual comprising the step of administering to the individual a therapeutic amount of a compound of claim 1.

Claim 34 (new): The method of claim 33, wherein the cancer is breast cancer.

Claim 35 (new): A method of treating cancer in an individual comprising the step of administering to the individual a therapeutic amount of a compound of claim 4.

Claim 36 (new): The method of claim 35, wherein the cancer is breast cancer.

Claim 37 (new): A compound of claim 3, further comprising a pharmaceutically acceptable excipient.

Claim 38 (new): A compound of claim 4, further comprising a pharmaceutically acceptable excipient.